New drug cocktail aims to shrink head and neck tumors before surgery

NCT ID NCT07550972

ENROLLING_BY_INVITATION Disease control Sponsor: Zhejiang Provincial People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether combining two drugs, pertuzumab and lenvatinib, can shrink tumors before surgery in people with advanced head and neck cancer. About 30 participants will receive 2-4 cycles of the drug combination, then undergo surgery. The main goal is to see how many tumors respond completely or nearly completely to the treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pertuzumab and lenvatinib
What this could lead to: If successful, this combination could shrink tumors before surgery, potentially improving outcomes for patients with advanced head and neck cancer.
What could go wrong: This is a small, early-phase trial with only 30 participants and no comparison group. The treatment may not work as hoped, and side effects from the drug combination could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK

Contacts and locations

Locations

Zhejiang Provincial People's Hospital

Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.